Who is sponsoring NCT04174339?

NCT04174339 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT04174339?

Interventions in NCT04174339: Camrelizumab, Apatinib Mesylate, POF.

What condition does NCT04174339 study?

NCT04174339 studies Advanced Gastric Adenocarcinoma.

Is NCT04174339 still recruiting?

NCT04174339 is currently status unknown. Last updated 22 November 2019.

Last reviewed 2019-11-22 · How we verify

NCT04174339

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Status unknown NA Last updated 22 November 2019

What this trial tests

NA trial testing Camrelizumab in Advanced Gastric Adenocarcinoma in 20 participants. Status unknown.

Timeline

10 December 2019

Primary endpoint
9 December 2020

2 May 2021

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	10 December 2019
Primary completion	9 December 2020
Estimated completion	2 May 2021
Sites	1 location across China

Drugs / interventions tested

Camrelizumab — full drug profile →
Apatinib Mesylate
POF — full drug profile →

Conditions studied

Advanced Gastric Adenocarcinoma — all drugs for Advanced Gastric Adenocarcinoma →

Sponsor

Fujian Cancer Hospital

Who can join

Adults 18 to 70, any sex, with Advanced Gastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single center, phase II study, to evaluate the effectiveness and safety of PD-1 Antibody(SHR-1210) Plus apatinib Combined With POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the first-line treatment for patients with advanced/metastatic gastric cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer.
Cui Q, Mao Y, Wu D, Hu Y, et al · · 2022 · cited 5× · PMID 36387189 · DOI 10.3389/fonc.2022.952494
Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.
Wang J, Lin J, Wang R, Tong T, et al · · 2024 · cited 3× · PMID 38760737 · DOI 10.1186/s12885-024-12340-4

Verify or expand the search:

Other trials of Camrelizumab

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting

Other recruiting trials for Advanced Gastric Adenocarcinoma

Currently open trials in the same condition.

NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
NCT06203600 — Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · Phase 2, PHASE3 · recruiting
NCT05677490 — mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg · Phase 3 · recruiting
NCT05041153 — Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma · EARLY_PHASE1 · recruiting
NCT04209686 — Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma · Phase 2 · active not recruiting

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04174339 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 22 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04174339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing